Summary & Overview

Seizures without MCC: Inpatient Reimbursement Overview

DRG 101 covers inpatient stays for seizures when no Major Complication or Comorbidity is present, encompassing acute or breakthrough seizure events that do not drive high resource use. Correct assignment to this Diagnosis-Related Group matters for inpatient reimbursement because it determines the prospective payment rate under Medicare and impacts hospital payment for the episode of care.

Seizures without Major Complication or ComorbidityDRG Seizures without MCCDRG 101Diagnosis-Related GroupInpatient ReimbursementMedicareNeurologyEpilepsyEmergency Medicine

DRG 101 Overview

DRG 101 covers inpatient admissions where the principal diagnosis is seizures without a Major Complication or Comorbidity and where no secondary diagnoses qualify as a Major Complication or Comorbidity. This Diagnosis-Related Group typically includes patients with acute seizure events, breakthrough seizures in known epilepsy, or single provoked seizures that do not require advanced resource use. It matters for Medicare payment because classification into this Diagnosis-Related Group determines the prospective payment rate and influences hospital reimbursement for the inpatient stay. Accurate coding and documentation of seizure etiology and comorbid conditions affect whether an admission is assigned to this Diagnosis-Related Group or to a higher-paying group.

National Payment Rates

Across commercial payers, negotiated rates for DRG 101 range from about $8.2K (BCBS) up to $15K (Aetna and Cigna median ranges by payer), with individual payer medians reported between $8.1K and $16K — the widest spread between payer medians is roughly $8K. See the table and chart below for payer-level distributions and percentile detail. Payer distributions include Aetna, Cigna, Anthem, and BCBS as shown.

Mean Rates by Payer — National — DRG 101

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Payer rates in Alaska for DRG 101 range from $14K to $22K across the reported payers, with Anthem and Blue Cross Blue Shield clustered at $14K and Cigna at $22K. The notable deviation is Cigna’s mean, which sits well above the other local payers and above many national medians. Refer to the table and chart below for payer-level detail.

Key Insights for Alaska

Highest payer: Cigna (mean $22K); Lowest payers: Anthem and Blue Cross Blue Shield (mean $14K each).
Cigna in Alaska pays substantially above the other local payers and is materially higher than national BCBS and Anthem medians, indicating a pronounced in-state premium for Cigna relative to the AK payer set.

Clinical Trials

Acute emergency management trials: Studies focusing on rapid ED and inpatient treatments for patients presenting with new-onset seizures or breakthrough seizures without major complications evaluate time-to-seizure-control interventions, dosing strategies, and protocols for safe observation versus admission. These trials enroll adults and children who present with isolated seizure events or short seizure clusters but without life‑threatening comorbidities, aiming to define best practices that reduce inpatient length of stay and avoid unnecessary escalation of care. Results are directly relevant to hospital clinicians and payers because optimized acute pathways can lower resource utilization and readmission risk while ensuring safe disposition decisions.
Comparative effectiveness and medication strategy studies: Research comparing anticonvulsant selection, initiation versus deferment of chronic therapy, or route and timing of administration among patients admitted for seizures without major complications examines outcomes such as seizure recurrence, adverse events, and functional recovery. These studies typically include patients with provoked or unprovoked seizures who do not meet criteria for major complications or prolonged ICU stays, and they seek to identify which medication strategies best balance seizure control with side‑effect profiles. Findings inform inpatient prescribing practices, formulary decisions, and length‑of-stay considerations that impact reimbursement and overall cost of care.
Post-discharge outcomes and care coordination studies: Observational cohorts and interventional trials testing transitional-care models, outpatient neurology follow‑up timing, and patient education/self‑management programs target patients discharged after a seizure hospitalization without major complications to reduce recurrence, emergency visits, and readmissions. These studies measure metrics such as outpatient visit adherence, subsequent ED use, functional status, and medication adherence over weeks to months, enrolling patients considered stable enough for routine discharge. For providers and payers, evidence from these studies supports effective discharge planning and care pathways that can improve patient safety while lowering downstream acute-care costs.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$9.1K	$45K	$6.9K	28K

Acute emergency management trials: Studies focusing on rapid ED and inpatient treatments for patients presenting with new-onset seizures or breakthrough seizures without major complications evaluate time-to-seizure-control interventions, dosing strategies, and protocols for safe observation versus admission. These trials enroll adults and children who present with isolated seizure events or short seizure clusters but without life‑threatening comorbidities, aiming to define best practices that reduce inpatient length of stay and avoid unnecessary escalation of care. Results are directly relevant to hospital clinicians and payers because optimized acute pathways can lower resource utilization and readmission risk while ensuring safe disposition decisions.
Comparative effectiveness and medication strategy studies: Research comparing anticonvulsant selection, initiation versus deferment of chronic therapy, or route and timing of administration among patients admitted for seizures without major complications examines outcomes such as seizure recurrence, adverse events, and functional recovery. These studies typically include patients with provoked or unprovoked seizures who do not meet criteria for major complications or prolonged ICU stays, and they seek to identify which medication strategies best balance seizure control with side‑effect profiles. Findings inform inpatient prescribing practices, formulary decisions, and length‑of-stay considerations that impact reimbursement and overall cost of care.
Post-discharge outcomes and care coordination studies: Observational cohorts and interventional trials testing transitional-care models, outpatient neurology follow‑up timing, and patient education/self‑management programs target patients discharged after a seizure hospitalization without major complications to reduce recurrence, emergency visits, and readmissions. These studies measure metrics such as outpatient visit adherence, subsequent ED use, functional status, and medication adherence over weeks to months, enrolling patients considered stable enough for routine discharge. For providers and payers, evidence from these studies supports effective discharge planning and care pathways that can improve patient safety while lowering downstream acute-care costs.

OpenPayer

Summary & Overview

Seizures without MCC: Inpatient Reimbursement Overview

DRG 101 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes